<DOC>
	<DOCNO>NCT00006264</DOCNO>
	<brief_summary>RATIONALE : Antiviral drug zidovudine ganciclovir act virus may effective treatment HIV . Interleukin-2 may stimulate person 's white blood cell kill lymphoma cell . Combining treatment may effective treat AIDS-related primary central nervous system lymphoma . PURPOSE : Phase II trial study effectiveness combine zidovudine , ganciclovir , interleukin-2 treating patient AIDS-related primary central nervous system lymphoma .</brief_summary>
	<brief_title>Zidovudine Plus Interleukin-2 Ganciclovir Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity zidovudine , interleukin-2 , ganciclovir patient AIDS relate primary central nervous system lymphoma . - Determine response rate overall survival patient treat regimen . OUTLINE : This multicenter study . - Induction therapy : Patients receive zidovudine ( AZT ) IV ganciclovir IV 1 hour every 12 hour day 1-14 . Patients also receive interleukin-2 ( IL-2 ) IV every 12 hour day 1-14 combination antiretroviral therapy consist nucleoside reverse transcriptase inhibitor ( one must AZT ) , nonnucleoside reverse transcriptase inhibitor , protease inhibitor . AZT ganciclovir treatment continue additional 7 day partial response achieve . - Maintenance therapy : Patients receive IL-2 subcutaneously 3 time week 6 month . Patients also receive oral ganciclovir 3 time day combination antiretroviral therapy ( AZT allow , require ) . Treatment continue absence disease progression unacceptable toxicity . Patients follow monthly 1 year , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 10-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HIV positive Diagnosis central nervous system lymphoma one following mean : Brain biopsy Thallium spectroscopy scan conjunction CT scan MRI fail improve least 2 week antitoxoplasmosis therapy Cerebral spinal fluid positive Epstein Barr virus conjunction positive thallium spectroscopy scan Thallium spectroscopy scan demonstrate thallium retention index great 1 Documented intracranial space occupy lesion No systemic nonHodgkin 's lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,000/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin SGOT great 3 time upper limit normal No major hepatic dysfunction evidence encephalopathy , ascites , varix Renal : Creatinine clearance least 60 mL/min Other : No prior malignancy within past 5 year except carcinoma situ cervix , basal cell carcinoma skin , Kaposi 's sarcoma require systemic therapy No active uncontrolled infection except HIV Epstein Barr virus No known allergy E. coli derive product Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Concurrent corticosteroid allow Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
</DOC>